Research graph
References from Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation. Local targets link to admitted publications; unresolved targets remain external evidence.
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
10.1161/01.cir.0000140263.20897.42 · 2004 · External reference
Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association
10.1161/cir.0000000000000659 · 2019 · External reference
Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study
10.1136/bmj.k1453 · 2018 · External reference
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
10.1016/j.hrthm.2017.05.012 · 2017 · External reference
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
10.1093/eurheartj/ehaa612 · 2021 · External reference
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
10.1093/eurheartj/ehy176 · 2018 · External reference
Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study
10.1111/jce.12928 · 2016 · External reference
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
10.1007/s40262-019-00775-z · 2019 · External reference
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
10.1093/europace/euab065 · 2021 · External reference
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
2016 · External reference
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
10.1093/ehjcvp/pvaa017 · 2021 · External reference
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
10.1016/j.chest.2018.07.040 · 2018 · External reference
A new equation to estimate glomerular filtration rate
10.7326/0003-4819-150-9-200905050-00006 · 2009 · External reference
Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application
10.1097/ftd.0000000000000509 · 2018 · External reference
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
10.1111/j.1365-2125.2012.04369.x · 2013 · External reference
Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes
10.1056/nejmoa1611179 · 2017 · External reference
Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
10.1056/nejmsa1616035 · 2017 · External reference
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure
10.1182/bloodadvances.2020002335 · 2020 · External reference
Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban
10.1177/1060028017738262 · 2018 · External reference
Direct oral anticoagulant concentrations and adherence in stroke patients
2023 · External reference
Bridging the gap: ageing, pharmacokinetics and pharmacodynamics
10.1211/0022357056163 · 2005 · External reference
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban
10.1007/s40262-014-0228-0 · 2015 · External reference
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
10.1002/jcph.633 · 2016 · External reference
Sex-Related Differences in Pharmacokinetics and Pharmacodynamics of Frequently Prescribed Drugs: A Review of the Literature
10.1007/s12325-019-01201-3 · 2020 · External reference
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
10.1016/j.thromres.2015.12.001 · 2016 · External reference
Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study
10.1111/jth.15563 · 2022 · External reference
Unresolved reference
2023 · External reference
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
10.1055/s-0038-1627480 · 2018 · External reference
Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation
10.1016/j.thromres.2015.04.030 · 2015 · External reference
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
10.1093/europace/euv421 · 2016 · External reference
Current Situation of Medication Adherence in Hypertension
10.3389/fphar.2017.00100 · 2017 · External reference
Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group
10.1016/j.jval.2018.08.006 · 2019 · External reference
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs—midazolam and odanacatib
10.1002/jcph.338 · 2014 · External reference
